ICCS 2024

Corporate Workshops

Corporate Workshops


The Corporate Workshop session will take place on Sunday, October 6 from 12:00 PM - 2:00 PM  and offer an opportunity for you to hear about the latest products from the participating companies. There is no charge to attend. The first 100 attendees to arrive by 12:10 PM, will receive a 10 USD Visa gift card, while supplies last.

12:00 PM - Cytek Biosciences

    “Enabling Operational Efficiencies In High-Parameter Leukemia And Lymphoma Subtyping Using Cytek AuroraTM Full Spectrum Flow Cytometers”

    David Ng, MD, FCAP
    Director of Flow Cytometry and Applied AI
    ARUP Laboratories

    Flow cytometry is routinely used in clinical laboratories for the diagnosis of leukemia and lymphoma as well as quantifying levels of measurable residual disease (MRD) during and after treatment. Using Cytek’s Full Spectrum ProfilingTM (FSPTM) technology in the clinical laboratory provides advantages regarding the ability to multiplex and obtain high quality data over conventional cytometry. These advantages are especially important in the performance of MRD assays. In this presentation, we will discuss the utility of using Cytek's spectral flow cytometers in ordinary leukemia and lymphoma subtyping, focusing on operational efficiencies as well as the benefits in diagnostics. With the five laser Cytek Aurora spectral flow cytometer, we were able to combine up to 36 markers in one diagnostic tube leading to improved efficiency and greater information. We will also present our strategy to characterize the panel performance on different sample and disease types as well as comparisons to our current 10-color triage panels. Moreover, we will show the equivalency in results obtained across our two Cytek Aurora instruments, indicating that harmonization of highly complex assays using Cytek's full spectrum cytometers is easily achieved. In conclusion, our experience in adoption of FSP technology in the clinical laboratory provides significant advantages and should be considered moving forward.

12:30 PM - BD Biosciences

    “BD FACS: 50 Years Enabling Science Through Flow Cytometry”

    Rodrigo Pestana, PhD
    Sr Scientific Manager
    BD Biosciences

    Flow cytometry is a versatile technology initially used in clinical sciences to aid in the diagnosis, monitoring, and treatment response of hematological and infectious conditions. Its applications have since expanded to include transplantation and transfusion, identification of immune disorders, and monitoring immune responses. Nowadays, flow cytometry is routinely applied to support the diagnosis and classification of blood cancers and detect minimal/measurable residual disease, to identify and quantify different types of immune cells for various disorders and disease states, as well as for numerous applications from basic to applied sciences, including some involved in drug development and translational research.

    Partnership between industry, academy and clinical scientists have shaped and enhanced our understanding of immunology, cell biology, and hemato-oncology through the continuous evolution of flow cytometry. Our talk celebrates 50 years of innovative contributions from BD and scientists in the field of flow cytometry since the introduction of the Fluorescence Activated Cell Sorter (FACS), in 1974. This journey of perpetual innovation includes the development of monoclonal antibodies, fluorochromes, and technologies that transformed flow cytometry from a single-parameter technique into a method that generates high-parameter data for detailed analysis of individual cells using powerful bioinformatics.

    1:00 PM - Sysmex America, Inc.

      "Validation of a High-Sensitivity 10-Color Flow Cytometric Measurable Residual Disease Assay for Multiple Myeloma"

      Melissa Ulas MD, PhD
      Medical Director Clinical Laboratory, Temple Health Chestnut Hill Hospital
      Interim Medical Director Clinical Laboratory, TUH Episcopal Hospital
      Assistant Professor, Clinical Pathology and Laboratory Medicine, Lewis Katz School of Medicine, Temple University
      Associate Director, Clinical Chemistry and POCT, Pathology and Laboratory Medicine, Temple University Hospital System

      Flow cytometric (FC) detection of measurable residual disease (MRD) in multiple myeloma (MM) is predictive of response to therapy. The investigators developed and validated a high-sensitivity single tube 10-color MM MRD assay. The panel included VS38c and CD138 as backbone markers to detect plasma cells and combine surface and cytoplasmic markers into a single tube following bulk lysis. During this session, the primary investigator will share her team's findings in the validation of the MDR assay using the Sysmex XF-1600TM Flow Cytometer for research use only* and the VenturiOne© Flow Cytometry analysis Software.

      Overview
      1. Explain key steps needed to complete the MRD assay validation.
      2. Discuss the benefits of of using the Sysmex XF-1600 and the VenturiOne software to validate flow cytometry assays.
      3. Recognize the regulatory considerations needed to effectively validate flow cytometry assays.

      *XF-1600 is For Research Use Only. Not for use in diagnostic procedures. RUO instruments must be validated before use in clinical practice.

    1:30 PM - Beckman Coulter

      “Optimized Workflow for Clinical Flow Cytometry Lab”

      Alan Dunlop
      Royal Marsden Hospital NHS Trust
      London, UK

      Year on year clinical flow cytometry laboratories see an increase in not only sample numbers but in the complexity of testing required. There is a similar increase in the volume of quality related tasks required to ensure laboratories maintain accreditation.

      This increased workload rarely comes with appropriate resource meaning staff are constantly under pressure to do more in the same number of hours. In an attempt to deal with this rising tide of work our laboratory has undertaken a complete overhaul of the way we function, we have implemented new high parameter flow cytometers, fully automated sample preparation for leukaemia and lymphoma diagnostic testing as well as stem cell enumeration. With the implementation of a new laboratory information system, we have become paper free. This along with offline data analysis has allowed us to facilitate effective remote work at times for over 60% of our staff. This transformation of the way we work has allowed us to focus on developing our next generation of Scientists by training then in data analysis, challenging them with research projects and involving them in quality tasks when previously simply delivering our clinical service was a challenge.

2111 Chestnut Street, Ste 145
     Glenview, IL 60025 USA
Phone: 847-550-3080
Website: www.cytometry.org
Email: info@cytometry.org

© All Rights Reserved. SPLtrak, Inc.